Eyepoint, Inc. · NASDAQ:EYPT
Eyepoint — EyePoint Pharmaceuticals — Investor Presentation (July 2023)
33 slides from Eyepoint's investor presentation, Jul 11, 2023
Slide 1: Investor Presentation July 2023
Investor Presentation July 2023 Exhibit 99.1
Slide 2: Forward-Looking Statements
Forward-Looking Statements Various statements made in this presentation are forward-looking, within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, and are inherently subject to risks, uncertainties and potentially inaccurate assumptions. All statements that address activit
Slide 3: Committed to developing therapeutics to improve the lives of patients with serious eye disorders
Committed to developing therapeutics to improve the lives of patients with serious eye disorders COMPANY OVERVIEW 3 | INVESTOR PRESENTATION Pipeline represents multi billion-dollar product opportunities EYP-1901 –bioerodible intravitreal (IVT) insert of proprietary tyrosine kinase inhibitor (TKI) vo
Slide 4: Pipeline Represents Multibillion Dollar Product Opportunities
Pipeline Represents Multibillion Dollar Product Opportunities Program Indication Discovery Pre-Clin Phase 1 Phase 2 Phase 3 Next Milestone EYP-1901 – (vorolanib in Durasert E™) wet AMD NPDR DME ack Complement programs GA Topline data in Q2 2024 Topline data in December 2023 single dose 6-month maint
Slide 5: Durasert Technology: Safe Sustained IVT Drug Delivery
DURASERT® TECHNOLOGY 5 | INVESTOR PRESENTATION Safe Sustained IVT Drug Delivery Used in four of six FDA approved intravitreal sustained delivery products Delivered by a single in-office IVT injection Continuous, stable release of drug Zero-order kinetics release Durasert® : non-erodible YUTIQ® (Alim
Slide 6: EYP-1901 Delivers VEGF Receptor Binding Vorolanib Using Durasert E
EYP-1901 Delivers VEGF Receptor Binding Vorolanib Using Durasert E™ Each insert ~1/5000 of vitreous volume A single IVT injection New MOA in potential treatment of VEGF mediated retinal diseases Positioned to be complementary to approved anti-VEGF therapies Sustained delivery of drug between ~8-9 mo
Slide 7: Vorolanib is a selective pan-VEGF receptor blocker
Vorolanib is a selective pan-VEGF receptor blocker WHY VOROLANIB? Composition of matter patent into 2037 Previous Phase 1 and Phase 2 clinical trials in wet AMD as an oral therapy showed compelling safety and efficacy data with no ocular toxicity observed1,2 In-vivo studies demonstrate encouraging n
Slide 8: Vorolanib Binds Receptors of All VEGF Growth Factors
Vorolanib Binds Receptors of All VEGF Growth Factors With Strong Affinity To VEGF Receptor 2 - A Receptor Associated With Blood Vessel Leakage VOROLANIB VOROLANIB VOROLANIB VEGF-A VEGF-B VEGF-C VEGF-D R1 | Inflammation R2 | Blood Vessel Leakage R3 | Blood Vessel Growth & Leakage 8 | INVESTOR PRESENT
Slide 9: EYP-1901 Phase 1 DAVIO Clinical Trial Results
EYP-1901 PHASE 1 DAVIO CLINICAL TRIAL RESULTS 9 | INVESTOR PRESENTATION
Slide 10: EYP-1901 Phase 1 DAVIO Clinical Trial Met All Objectives
EYP-1901 Phase 1 DAVIO Clinical Trial Met All Objectives FAVORABLE SAFETY PROFILE Stabilization of mean BCVA and OCT throughout 6 months was achieved 53% up to 6-months with no anti-VEGF supplemental injection 75% reduction in treatment burden at 6-months No ocular SAEs reported No drug-related syst
Slide 11: Favorable safety profile
Favorable safety profile No ocular serious adverse events (SAEs) No drug related systemic SAEs No drug related ocular or systemic toxicity No Durasert related toxicity or tolerance issues No dose limiting toxicity No ocular AEs of key interest observed No vitreous floaters, endophthalmitis, retinal
Slide 12: BCVA and CST Stable After Single Treatment of EYP-1901
BCVA and CST Stable At 6 And 12 Months After Single Treatment Of EYP-1901 In The DAVIO Clinical Trial AVERAGE CHANGE IN BCVA FROM SCREENING VISIT AVERAGE CHANGE IN CST FROM SCREENING VISIT ALL (N=17) MONTHS ALL (N=17) MONTHS BCVA: best corrected visual acuity OCT: optical coherence tomography; CST:
Slide 13: Reduction In Treatment Burden Of 75% At 6-Months
EYP-1901 Phase 1 DAVIO Clinical Trial Demonstrated Clinically Significant Reduction In Treatment Burden Of 75% At 6-Months 13 | INVESTOR PRESENTATION SOC Anti-VEGF Injections Before and After Treatment SOC (Anti-VEGF) + EYP-1901 Anti-VEGF No supplemental injection Missed visit Low dose (n=3) –70% Lo
Slide 14: Reduction In Treatment Burden Of 73% At 12-Months
EYP-1901 Phase 1 DAVIO Clinical Trial Maintained A Clinically Significant Reduction In Treatment Burden Of 73% At 12-Months 14 | INVESTOR PRESENTATION SOC Anti-VEGF Injections Before and After Treatment SOC (Anti-VEGF) + EYP-1901 Anti-VEGF No supplemental injection Missed visit Low dose (n=3) –66% L
Slide 15: 53% Of Patients Did Not Require Supplemental Anti-VEGF At 6-Months
EYP-1901 Phase 1 DAVIO Clinical Trial Demonstrated That 53% Of Patients Did Not Require Supplemental Anti-VEGF Treatment At 6-Months 35% 47% 41% 41% 71% 76% 35% 35% 53% 82% 82% 100% Median time to supplemental anti-VEGF: 6 months 15 | INVESTOR PRESENTATION
Slide 16: DAVIO Subgroup Analysis – Nine Subjects With No Excess Fluid at Screening
PHASE 1 DAVIO CLINICAL TRIAL SUBGROUP ANALYSIS – NINE SUBJECTS WITH NO EXCESS FLUID AT SCREENING 16 | INVESTOR PRESENTATION EYP-1901
Slide 17: DAVIO Subgroup Showed Stable BCVA and CST At 6-Months
BCVA: best corrected visual acuity Mean change in BCVA from screening visit Mean change in CST from screening visit BCVA = -0.4 letters at 6 months CST on OCT = -1.0 microns at 6 months OCT: optical coherence tomography; CST: central subfield thickness DAVIO Subgroup of Eyes with No Excess Fluid At
Slide 18: DAVIO Subgroup Showed Stable BCVA and CST Through 12-Months
DAVIO Subgroup With No Excess Fluid At Screening Showed Stable BCVA and CST Through 12-Months Mean change in BCVA from screening visit Mean change in CST from screening visit BCVA = -0.4 letters at 6 months +0.7 letters at 11 months -2.2 letters at 12 months CST on OCT = -1.0 microns at 6 months +0.
Slide 19: Subgroup Reduction In Treatment Burden At 6 Months
DAVIO Subgroup With No Excess Fluid At Screening Showed A 92% Reduction In Treatment Burden At 6 Months SOC (Anti-VEGF) + EYP-1901 Low dose (n=2) -89% Low-mid dose (n=1) -100% Mid dose (n=5) -90% High dose (n=1) -100% SOC Anti-VEGF Injections Before and After Treatment Reduction in Average Monthly T
Slide 20: Subgroup 89% Reduction In Treatment Burden At 12-Months
SOC (Anti-VEGF) + EYP-1901 SOC Anti-VEGF Injections Before and After Treatment SOC (Anti-VEGF) + EYP-1901 Anti-VEGF No supplemental injection Missed visit Low dose (n=2) -83% Low-mid dose (n=1) -100% Mid dose (n=5) -90% High dose (n=1) -83% Reduction in Average Monthly Treatment Burden at 12 Months
Slide 21: 67% Did Not Require Supplemental Anti-VEGF Injection At 6-Months
DAVIO Subgroup With No Excess fluid At Screening Demonstrated That 67% Did Not Require A Supplemental Anti-VEGF Injection At 6-Months Median time to supplemental anti-VEGF: 12 months 56% 67% 67% 67% 89% 56% 56% 67% 100% 100% 100% 100% DAVIO 12-month final data 21 | INVESTOR PRESENTATION
Slide 22: EYP-1901 Treat to Maintain in Wet AMD
EYP-1901 TREAT TO MAINTAIN IN WET AMD 22 | INVESTOR PRESENTATION
Slide 23: DAVIO Data Supports Advancing EYP-1901 As Maintenance Treatment For Wet AMD
DAVIO Clinical Trial Data Supports Advancing EYP-1901 As A Maintenance Treatment For Wet AMD About half of eyes in DAVIO could go up to 6 months on EYP-1901 alone Another ~30% received only a single supplemental anti-VEGF during 6-months About 15 % failed both SoC and EYP-1901 and required multiple
Slide 24: EYP-1901 Is Advancing As A Potential Maintenance Therapy In Wet AMD
EYP-1901 Is Advancing As A Potential Maintenance Therapy In Wet AMD Treat newly diagnosed patients with anti-VEGF of choice to reach desired “dry” outcome Maintain with EYP-1901on six-month intervals providing new MOA and sustained delivery Supplement with current anti-VEGF biologic, if needed 24 |
Slide 25: Wet AMD Phase 2 Clinical Trial - DAVIO 2 EYP-1901
WET AMD PHASE 2 CLINICAL TRIAL - DAVIO 2 25 | INVESTOR PRESENTATION EYP-1901
Slide 26: DAVIO 2 Designed to Support Initiation of Phase 3 Trials in 2024
The Phase 2 DAVIO 2 clinical trial for EYP-1901 in wet AMD was designed to support initiation of Phase 3 clinical trials in 2024 Phase 2 design includes DAVIO Phase 1 learnings and FDA interaction Type C meetings held with FDA CST below 350um at screening to eliminate poor responders to standard of
Slide 27: DAVIO 2 Is Randomized, Double-Masked, Aflibercept Controlled
EYP-1901 Phase 2 DAVIO 2 Clinical Trial Is Randomized, Double-Masked, Aflibercept Controlled With A Single EYP-1901 Treatment At Two Doses -D14 to -D7 D1 W4 W8 W12 W16 W24 W32 W36 to W56 W20 W28 EYP-1901 2mg low dose EYP-1901 3mg high dose Aflibercept q8W RANDOMIZATION REQUIRED AFLIBERCEPT INJECTION
Slide 28: Non-Proliferative Diabetic Retinopathy - Phase 2 Clinical Trial (PAVIA)
NON-PROLIFERATIVE DIABETIC RETINOPATHY - PHASE 2 CLINICAL TRIAL (PAVIA) 28 | INVESTOR PRESENTATION EYP-1901
Slide 29: Growing Global Diabetic Retinopathy Market
Diabetic Retinopathy Market Size Report. 2018-2020 (GrandViewResearch.com), Global Diabetic Retinopathy Market Size Report. Jan. 2022 (MarketDataForecast.com) Growing Global DR Market $12.27B Analysis includes North America, Europe, Asia Pacific, Latin America, Middle East, and Africa $12.27 billion
Slide 30: PAVIA Is Randomized Double-Masked, Single Injection With Sham Control
EYP-1901 Phase 2 PAVIA Clinical Trial Is Randomized Double-Masked, Single Injection With Sham Control As A 9-Month Treatment In NPDR EYP-1901 DOSING VISIT SCHEDULED SHAM INJECTION -D21 to –D5 D1 W4 W12 W24 W36 W48 EYP-1901 2mg low dose (n=35) EYP-1901 3mg high dose (n=35) Control Sham (n=35) RANDOMI
Slide 31: Solid cash position and cash runway into 2025
Solid cash position and cash runway into 2025 while funding Phase 2 trials for EYP-1901 BALANCE SHEET Strong Balance Sheet ~$142M of cash and investments on June 30, 2023 All bank debt retired in May 2023 Cash runway into 2025 31 | INVESTOR PRESENTATION
Slide 32: Continued Execution And Well Funded Through Key EYP-1901 Milestones
Continued Execution And Well Funded Through Key EYP-1901 Milestones EYP-1901 Corporate ✓ DAVIO 1 trial complete 2Q 2022 ✓ DAVIO 2 trial initiated 3Q 2022 ✓ PAVIA trial initiated 3Q 2022 ✓ DAVIO 2 enrollment complete 1Q 2023 ✓ PAVIA enrollment complete 2Q 2023 DAVIO 2 topline data December 2023 DME T
Slide 33: Investor Presentation July 2023
Investor Presentation July 2023
EyePoint Pharmaceuticals — Investor Presentation (July 2023) on 6ix